Insmed Inc
Insmed Incorporated develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company offers ARIKAYCE for the treatment of refractory nontuberculous mycobacterial lung infections, as well as is in phase 3 clinical trial for the treatment of mycobacterium avium complex lung disease as part of a combination antiba… Read more
Insmed Inc (INSM) - Net Assets
Latest net assets as of September 2025: $945.57 Million USD
Based on the latest financial reports, Insmed Inc (INSM) has net assets worth $945.57 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($2.36 Billion) and total liabilities ($1.42 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $945.57 Million |
| % of Total Assets | 40.05% |
| Annual Growth Rate | 18.09% |
| 5-Year Change | 3.44% |
| 10-Year Change | -8.44% |
| Growth Volatility | 441.2 |
Insmed Inc - Net Assets Trend (1999–2024)
This chart illustrates how Insmed Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Insmed Inc (1999–2024)
The table below shows the annual net assets of Insmed Inc from 1999 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $285.38 Million | +185.98% |
| 2023-12-31 | $-331.92 Million | -477.40% |
| 2022-12-31 | $87.95 Million | -78.57% |
| 2021-12-31 | $410.47 Million | +48.78% |
| 2020-12-31 | $275.88 Million | +5.43% |
| 2019-12-31 | $261.67 Million | +25.64% |
| 2018-12-31 | $208.27 Million | -42.32% |
| 2017-12-31 | $361.06 Million | +133.72% |
| 2016-12-31 | $154.48 Million | -50.44% |
| 2015-12-31 | $311.70 Million | +67.37% |
| 2014-12-31 | $186.24 Million | +29.94% |
| 2013-12-31 | $143.32 Million | +18.57% |
| 2012-12-31 | $120.88 Million | -9.97% |
| 2011-12-31 | $134.27 Million | -30.37% |
| 2010-12-31 | $192.84 Million | +55.63% |
| 2009-12-31 | $123.91 Million | +4489.44% |
| 2008-12-31 | $-2.82 Million | -124.57% |
| 2007-12-31 | $11.49 Million | -17.23% |
| 2006-12-31 | $13.88 Million | +31.83% |
| 2005-12-31 | $10.53 Million | +45.53% |
| 2004-12-31 | $7.24 Million | -72.41% |
| 2003-12-31 | $26.22 Million | +11.82% |
| 2002-12-31 | $23.45 Million | -60.72% |
| 2001-12-31 | $59.70 Million | -38.32% |
| 2000-12-31 | $96.78 Million | +2069.23% |
| 1999-12-31 | $4.46 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Insmed Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 433713669100.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $1.79 Million | 0.63% |
| Other Comprehensive Income | $-2.29 Million | -0.80% |
| Other Components | $4.65 Billion | 1627.94% |
| Total Equity | $285.38 Million | 100.00% |
Insmed Inc Competitors by Market Cap
The table below lists competitors of Insmed Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Fair Isaac Corporation
NYSE:FICO
|
$27.67 Billion |
|
TRIP.COM GROUP DL-00125
F:CLVB
|
$27.67 Billion |
|
AGNC Investment Corp
NASDAQ:AGNCL
|
$27.70 Billion |
|
CaixaBank S.A
PINK:CIXPF
|
$27.75 Billion |
|
Edison International
NYSE:EIX
|
$27.50 Billion |
|
Amrize Ltd
NYSE:AMRZ
|
$27.46 Billion |
|
Willis Towers Watson PLC
NASDAQ:WTW
|
$27.45 Billion |
|
KBC Groep NV
BR:KBC
|
$27.41 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Insmed Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from -331,923,000 to 285,379,000, a change of 617,302,000.
- Net loss of 913,772,000 reduced equity.
- New share issuances of 1,084,124,000 increased equity.
- Other comprehensive income decreased equity by 1,544,000.
- Other factors increased equity by 448,494,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-913.77 Million | -320.2% |
| Share Issuances | $1.08 Billion | +379.89% |
| Other Comprehensive Income | $-1.54 Million | -0.54% |
| Other Changes | $448.49 Million | +157.16% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Insmed Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 82.73x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 10.18x to 82.73x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1999-12-31 | $14.14 | $143.93 | x |
| 2000-12-31 | $52.83 | $143.93 | x |
| 2001-12-31 | $18.16 | $143.93 | x |
| 2002-12-31 | $7.09 | $143.93 | x |
| 2003-12-31 | $7.37 | $143.93 | x |
| 2004-12-31 | $1.85 | $143.93 | x |
| 2005-12-31 | $2.16 | $143.93 | x |
| 2006-12-31 | $1.46 | $143.93 | x |
| 2007-12-31 | $1.00 | $143.93 | x |
| 2008-12-31 | $-0.23 | $143.93 | x |
| 2009-12-31 | $9.74 | $143.93 | x |
| 2010-12-31 | $14.55 | $143.93 | x |
| 2011-12-31 | $5.75 | $143.93 | x |
| 2012-12-31 | $4.55 | $143.93 | x |
| 2013-12-31 | $4.10 | $143.93 | x |
| 2014-12-31 | $4.32 | $143.93 | x |
| 2015-12-31 | $5.32 | $143.93 | x |
| 2016-12-31 | $2.50 | $143.93 | x |
| 2017-12-31 | $5.42 | $143.93 | x |
| 2018-12-31 | $2.71 | $143.93 | x |
| 2019-12-31 | $3.09 | $143.93 | x |
| 2020-12-31 | $2.83 | $143.93 | x |
| 2021-12-31 | $3.66 | $143.93 | x |
| 2022-12-31 | $0.71 | $143.93 | x |
| 2023-12-31 | $-2.36 | $143.93 | x |
| 2024-12-31 | $1.74 | $143.93 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Insmed Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -320.20%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -251.24%
- • Asset Turnover: 0.18x
- • Equity Multiplier: 7.10x
- Recent ROE (-320.20%) is below the historical average (-133.21%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1999 | -174.66% | -779268.40% | 0.00x | 1.19x | $-8.24 Million |
| 2000 | -82.52% | -133103.33% | 0.00x | 1.06x | $-89.54 Million |
| 2001 | -62.26% | -12557.09% | 0.00x | 1.20x | $-43.14 Million |
| 2002 | -155.31% | -1862.76% | 0.07x | 1.21x | $-38.76 Million |
| 2003 | -39.28% | -6865.33% | 0.01x | 1.14x | $-12.92 Million |
| 2004 | -375.99% | -19856.20% | 0.01x | 1.80x | $-27.93 Million |
| 2005 | -388.73% | -31243.51% | 0.01x | 2.17x | $-41.98 Million |
| 2006 | -404.46% | -5664.88% | 0.03x | 2.04x | $-57.53 Million |
| 2007 | -173.76% | -265.13% | 0.39x | 1.70x | $-21.11 Million |
| 2008 | 0.00% | -133.92% | 2.46x | 0.00x | $-15.38 Million |
| 2009 | 95.51% | 1140.94% | 0.08x | 1.02x | $105.96 Million |
| 2010 | -3.34% | -92.96% | 0.04x | 1.02x | $-25.72 Million |
| 2011 | -44.44% | -1350.78% | 0.03x | 1.04x | $-73.09 Million |
| 2012 | -34.23% | 0.00% | 0.00x | 1.27x | $-53.46 Million |
| 2013 | -39.12% | -487.59% | 0.07x | 1.23x | $-70.41 Million |
| 2014 | -42.50% | -688.34% | 0.05x | 1.24x | $-97.78 Million |
| 2015 | -37.92% | 0.00% | 0.00x | 1.14x | $-149.35 Million |
| 2016 | -114.11% | 0.00% | 0.00x | 1.54x | $-191.72 Million |
| 2017 | -53.36% | 0.00% | 0.00x | 1.28x | $-228.75 Million |
| 2018 | -155.70% | -3297.17% | 0.02x | 2.90x | $-345.10 Million |
| 2019 | -97.20% | -186.37% | 0.18x | 2.84x | $-280.50 Million |
| 2020 | -106.60% | -178.87% | 0.21x | 2.89x | $-321.68 Million |
| 2021 | -105.89% | -230.63% | 0.15x | 3.03x | $-475.70 Million |
| 2022 | -547.50% | -196.26% | 0.15x | 18.83x | $-490.33 Million |
| 2023 | 0.00% | -245.59% | 0.23x | 0.00x | $-716.37 Million |
| 2024 | -320.20% | -251.24% | 0.18x | 7.10x | $-942.31 Million |
Industry Comparison
This section compares Insmed Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Insmed Inc (INSM) | $945.57 Million | -174.66% | 1.50x | $27.54 Billion |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |